There is no peace for the AstraZeneca vaccine. New concerns related to some episodes of rare blood clots detected in patients who had been inoculated led Germany to block the administration of the drug on subjects under 60 years of age. In the German vaccination program with AstraZeneca, therefore, only people aged 60 and over remain confirmed who do not belong to high risk categories for Covid-19 and who have in any case agreed to use AstraZeneca with their doctor.
The decision was taken by the Minister of Health, Jens Spahn, together with the representatives of the Laender, after the release by the Robert Koch-Institut, the medical regulatory body, of new data certifying that up to 29 March, 31 cases have been registered in Germany – out of approximately 2.7 million vaccinated with AstraZeneca – of rare blood clots in people who have recently undergone inoculations. Nine of these people died, seven of whom were women, aged between 20 and 63.
Already in recent weeks, various reports of a rare form of cerebral thrombosis had led to the temporary suspension of the use of AstraZeneca in many European countries, including Italy. The EMA subsequently expressed itself, reporting that on the basis of the first investigations carried out in relation to the reported cases, there was no clear correlation and that the benefits of the AstraZeneca vaccine outweighed the risks, recommending in any case to provide patients and doctors with warnings. about possible rare side effects.
Meanwhile, from 25 March the AstraZeneca vaccine changed its name and was officially renamed Vaxzevria. The decision, as communicated by the Anglo-Swedish pharmaceutical company itself, is due to the fact that the serum against Covid had a generic name: Covid-19 AstraZeneca vaccine, a simple acronym, while now it has been registered with a real name, as required by the practice of drugs.
On the website ofMom, the European Medicines Agency, a new “leaflet” of the vaccine was consequently published. The package leaflet with contraindications and side effects it also reports some new definitions that warn of recent adverse thromboembolic events, albeit rare.
In fact, first of all, we would like to inform you that this is a “Medicinal product subject to additional monitoring. This will allow the rapid identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions“.
In the section relating to special warnings, it is also specified that: “It was observed very rarely a combination of thrombosis and thrombocytopenia, in some almost accompanied from bleeding, afterwards to vaccination with Vaxzevria. This include severe cases presenting as thrombosis venous, including sites unusual such as thrombosis breast cerebral venous, thrombosis of the vena mesenteric and thrombosis arterial, concomitant with thrombocytopenia. The majority some of these cases do is verified within the first few iftte to fourteen days after vaccination and yes is verified in women of an inferior ageand 55 years old. However that could reflect the increase of use of the vaccine in this population. Some cases have been fatal“.
The EMA would like to point out once again that “the benefits of Vaxzevria in preventing Covid-19 continue to outweigh the risks, there are no recommended changes regarding the use of this vaccine“.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
